• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.
【24h】

Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases.

机译：Belimumab，一种抗BLyS人单克隆抗体，可潜在治疗炎性自身免疫疾病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: B lymphocyte stimulator (BLyS) is a factor determining the survival of B cells, and elevated levels in serum or locally have been observed in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients. Belimumab (LymphoStat-B), a human monoclonal antibody that inhibits BlyS, was developed for the treatment of these diseases. OBJECTIVE: To summarize preclinical development, efficacy and safety of belimumab in treatment of RA and SLE. METHODS: Articles found in a PubMed search and data presented in abstract form at international conferences up to August 2008 are described. RESULTS/CONCLUSIONS: Belimumab was well tolerated in treatment of RA over 24 weeks and SLE over 3 years. It significantly decreased rheumatoid factor (RF) levels, and modestly reduced symptoms of RA, especially in some subgroups such as patients with high disease activity, positive RF and no anti-TNF treatment experience. It also significantly reduced symptoms of SLE, and decreased anti-double-stranded DNA autoantibodies among patients with positive baseline anti-double-stranded DNA or antinuclear antibodies during a long-period treatment. These results suggest that careful patient selection is necessary to achieve optimal outcomes.
机译：背景：B淋巴细胞刺激物（BLyS）是决定B细胞存活的因素，在类风湿关节炎（RA）和系统性红斑狼疮（SLE）患者中，血清或局部水平升高。 Belimumab（LymphoStat-B）是一种抑制BlyS的人类单克隆抗体，已被开发用于治疗这些疾病。目的：总结贝利木单抗治疗RA和SLE的临床前进展，疗效和安全性。方法：描述了在PubMed搜索中找到的文章以及在2008年8月之前的国际会议上以抽象形式呈现的数据。结果/结论：贝利木单抗治疗RA 24周和SLE 3年耐受性良好。它显着降低了类风湿因子（RF）的水平，并适度减轻了RA的症状，特别是在某些亚组中，例如疾病活动活跃，RF阳性且没有抗TNF治疗经验的患者。在长期治疗期间，在基线抗双链DNA或抗核抗体为阳性的患者中，它还可显着减轻SLE症状，并降低抗双链DNA自身抗体。这些结果表明，仔细的患者选择对于实现最佳结果是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号